Retatrutide

Safety

The safety profile of retatrutide is still being established through ongoing clinical trials and post-marketing surveillance. Available evidence suggests a safety profile similar to other incretin-based therapies, though data remains limited.

Known Side Effects

Evidence for specific adverse events is thin, as most published studies focus on efficacy rather than detailed safety outcomes. Based on the available clinical trial data and the drug's mechanism as a triple receptor agonist (GLP-1, GIP, and glucagon receptors), the side effect profile likely resembles other incretin-based medications, though specific frequencies and severity data for retatrutide are not well-documented in the current literature.

Drug Interactions

Limited evidence exists regarding drug interactions. One completed Phase 1 study (NCT06808802) investigated retatrutide's effect on metoprolol pharmacokinetics, suggesting potential interactions with cardiovascular medications are being evaluated. However, specific interaction data and clinical significance are not available in the current evidence base.

Populations That Should Avoid It

Evidence regarding contraindications is extremely thin. While clinical trials have been conducted in adults with type 2 diabetes and obesity, specific populations that should avoid retatrutide have not been clearly defined in the available literature. One narrative review mentions use in adolescent obesity, but safety data for this population appears limited.

Special Considerations

A completed Phase 1 study (NCT05611957) evaluated retatrutide in participants with impaired renal function, suggesting kidney disease may require dose adjustments or special monitoring, though specific recommendations are not available in the current evidence.

Evidence Limitations

The safety evidence for retatrutide is notably thin. Most available studies focus on efficacy outcomes rather than comprehensive safety analyses. While clinical trials are ongoing or recently completed, detailed safety data from these studies have not been published in the peer-reviewed literature available for this review. Healthcare providers should exercise caution and closely monitor patients, as the full safety profile of this novel triple receptor agonist is still being established.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider for personalized medical guidance.